Audentes Therapeutics (BOLD) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Audentes Therapeutics (NASDAQ: BOLD) recently:

  • 3/15/2018 – Audentes Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 3/13/2018 – Audentes Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
  • 3/9/2018 – Audentes Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $56.00 price target on the stock.
  • 3/9/2018 – Audentes Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 3/9/2018 – Audentes Therapeutics was given a new $37.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 3/9/2018 – Audentes Therapeutics had its “buy” rating reaffirmed by analysts at William Blair.
  • 3/8/2018 – Audentes Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $37.00 price target on the stock. According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
  • 2/12/2018 – Audentes Therapeutics is now covered by analysts at Mizuho. They set a “neutral” rating and a $26.00 price target on the stock.
  • 2/9/2018 – Audentes Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
  • 2/7/2018 – Audentes Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.

Shares of BOLD stock opened at $29.93 on Tuesday. The company has a market capitalization of $1,070.15, a P/E ratio of -8.80 and a beta of 0.89. Audentes Therapeutics Inc has a 1-year low of $13.90 and a 1-year high of $41.80.

How to Become a New Pot Stock Millionaire

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.82) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.09. equities analysts forecast that Audentes Therapeutics Inc will post -3.43 earnings per share for the current fiscal year.

In other news, major shareholder Orbimed Advisors Llc sold 433,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $35.11, for a total transaction of $15,210,003.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 1,069,707 shares of company stock valued at $37,499,461. Corporate insiders own 47.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC grew its holdings in Audentes Therapeutics by 10.4% during the third quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock worth $21,885,000 after buying an additional 73,809 shares in the last quarter. Mckinley Capital Management LLC Delaware bought a new stake in Audentes Therapeutics during the third quarter worth $1,333,000. Victory Capital Management Inc. grew its holdings in Audentes Therapeutics by 23.2% during the fourth quarter. Victory Capital Management Inc. now owns 87,674 shares of the biotechnology company’s stock worth $2,740,000 after buying an additional 16,500 shares in the last quarter. Virtus Fund Advisers LLC bought a new stake in Audentes Therapeutics during the fourth quarter worth $372,000. Finally, Farallon Capital Management LLC bought a new stake in Audentes Therapeutics during the fourth quarter worth $9,989,000. Institutional investors and hedge funds own 66.96% of the company’s stock.

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Endologix  Stock Price Down 10.2%
Endologix Stock Price Down 10.2%
New Gold  Shares Gap Down to $2.49
New Gold Shares Gap Down to $2.49
InvestDigital  Price Hits $0.0556 on Exchanges
InvestDigital Price Hits $0.0556 on Exchanges
ICOBID  Price Hits $0.0013 on Exchanges
ICOBID Price Hits $0.0013 on Exchanges
SpaceChain  Market Cap Achieves $26.48 Million
SpaceChain Market Cap Achieves $26.48 Million
Patrick Industries, Inc.  Receives $75.25 Average Price Target from Analysts
Patrick Industries, Inc. Receives $75.25 Average Price Target from Analysts


© 2006-2018 Ticker Report. Google+.